Key result
NICD-CRT trial evaluates activated versus non-activated CRT in heart failure patients with NICD.
Why the study?
Does activated CRT improve clinical status in patients with heart failure, LVEF <35%, and non-specific intraventricular conduction delay compared to non-activated CRT?
RCT (n=200)
Double-blind
1:1
Yes
Does activated CRT improve clinical status in patients with heart failure, LVEF <35%, and non-specific intraventricular conduction delay compared to non-activated CRT?
The NICD-CRT study is designed to evaluate the efficacy of cardiac resynchronization therapy in heart failure patients with reduced ejection fraction and non-specific intraventricular conduction delay.
Answers are grounded in this paper and cite their sources.
CRT benefit uncertain in HF with NICD; this RCT will deliver first direct evidence on activation versus control.
INTRODUCTION: Cardiac resynchronisation therapy (CRT) was initially developed to treat patients with left bundle branch block (LBBB). However, many patients with heart failure have a widened QRS but neither left-BBB nor right-BBB; this is called non-specific intraventricular conduction delay (NICD). It is unclear whether CRT is effective in this subgroup of patients. METHODS AND ANALYSIS: The NICD-CRT study is a prospective, double-blind, randomised (1:1), parallel-arm, multicentre trial comparing the effects of CRT in patients with heart failure, a reduced left ventricular ejection fraction (LVEF <35%) and NICD, who have been implanted with a device (CRT-pacemaker or CRT-defibrillator) that has or has not been activated. Enrolment began on 15 July 2015 and should finish within 3 years; 40 patients have already been randomised and 11 centres have agreed to participate. The primary end point is the comparison of the proportion of patients improved, unchanged or worsened over the subsequent 12 months. 100 patients per group are required to demonstrate a difference between groups with a statistical power of 90%, a type I error of 0.05% (two-sided) and a loss to follow-up of 10%. This trial will add substantially to the modest amount of existing data on CRT in patients with NICD and should reduce uncertainty for guidelines and clinical practice when added to the pool of current information. ETHICS AND DISSEMINATION: Local ethics committee authorisations have been obtained since May 2015. We will publish findings from this study in a peer-reviewed scientific journal and present results at national and international conferences. TRIAL REGISTRATION NUMBER: NCT02454439; pre-results.
No takes yet. Share an insight, caveat, or question.
Eschalier et al. (2016) conducted an RCT in Heart failure with reduced left ventricular ejection fraction and non-specific intraventricular conduction delay (NICD) (n=200). Cardiac resynchronisation therapy (CRT) vs. CRT OFF (device implanted but inactivated) was evaluated on Composite of 12-month all-cause deaths and percentage of hospitalisations for heart failure at 12 months combined using an average z-score. The NICD-CRT study is a prospective, double-blind, randomized trial designed to evaluate the clinical effectiveness of cardiac resynchronization therapy in 200 heart failure patients with NICD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: